Retatrutide (LY3437943, Triple G) is a novel investigational triple hormone receptor agonist targeting GLP-1, GIP, and Glucagon receptors simultaneously, developed by Eli Lilly as the successor to Tirzepatide (Dual G). Unlike single GLP-1 (Semaglutide) that only suppresses appetite, or Dual GIP/GLP-1 (Tirzepatide) that adds insulin sensitization, Triple-G adds glucagon-driven energy expenditure and hepatic fat oxidation, achieving the highest weight loss ever recorded in incretin trials. Google Trends shows interest up 979% in 12 months, dominating all peptide searches in 2026. It is the top trending peptide for next-gen obesity pharmacotherapy research, triple agonist revolution paradigm shift, CagriSema vs Retatrutide head-to-head comparison, and oral peptide GLP-1 successor studies.
Retatrutide works via 3-receptor synergy. 1. GLP-1 AGONIST: Promotes satiety & appetite regulation in hypothalamus, enhances insulin secretion & glucose control, slows gastric emptying. Effect: Reduced caloric intake. 2. GIP AGONIST: Supports fat metabolism & energy balance in adipose tissue, improves adipose tissue function, enhances insulin sensitivity. Effect: Better fat handling & metabolic health. 3. GLUCAGON AGONIST: Increases energy expenditure & lipolysis in liver and brown adipose, supports lipid metabolism, increases hepatic fatty acid oxidation. Effect: Burns fat, increases resting energy. CLINICAL RESEARCH HIGHLIGHTS (Phase 2b / Phase 3 TRIUMPH-1): Mean Weight Reduction -24.2% at Week 48 (12mg), Up to -28.7% to -30.3% at Week 80-88 (max dose), HbA1c Reduction -2.1% Improved Glycemic Control, Once-Weekly Dosing Subcutaneous Injection Investigational. This triple mechanism explains why retatrutide outperforms Tirzepatide (Zepbound) and sets new high bar.
Our Retatrutide lineup is supplied as high-purity lyophilized powder (>99% HPLC) with COA. For triple-agonist research, Retatrutide 5mg (starter), 10mg (most requested), 15mg (advanced), 30mg (value – Phase 3 dose) are available. Retatrutide belongs to Fat Metabolism Peptides / GLP-1 Receptor Agonists category, Third-Generation sub-group, next-gen after Dual Agonist Tirzepatide. Often compared with CagriSema (Cagrilintide + Semaglutide) and Petrelintide (Amylin analog) as “What’s after GLP-1”. Stable 24 months at -20°C. For Research Use Only, not for human consumption.